Table 2.
Univariable and multivariable Cox regression analysis of miRisk and clinical covariates.
| Overall survival | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| Covariate | HR | 95% CI | p-value | HR | 95% CI | p-value |
| Training cohort | ||||||
| PD-L1 (≥50%) | 1.81 | 1.04–3.16 | 0.036 | 1.48 | 0.69–3.17 | 0.314 |
| ECOGa (>0) | 1.49 | 0.84–2.64 | 0.175 | 1.41 | 0.75–2.66 | 0.284 |
| Gender (male vs female) | 0.82 | 0.48–1.40 | 0.457 | 0.86 | 0.48–1.56 | 0.623 |
| Age (>75 years) | 1.27 | 0.67–2.41 | 0.470 | 1.25 | 0.58–2.69 | 0.577 |
| Therapy line incl. <IV (>2) | 1.43 | 0.35–5.93 | 0.621 | 1.61 | 0.34–7.58 | 0.549 |
| Substance (pembro vs nivo) | 0.60 | 0.33–1.07 | 0.085 | 0.96 | 0.44–2.10 | 0.926 |
| Histology (non-adeno vs adeno) | 1.19 | 0.70–2.04 | 0.519 | 1.22 | 0.68–2.19 | 0.513 |
| Smoking status (ever smoker vs other) | 0.67 | 0.29–1.57 | 0.356 | 0.68 | 0.24–1.94 | 0.472 |
| ANCb (>7.5) | 1.87 | 1.09–3.22 | 0.023 | 1.24 | 0.68–2.27 | 0.485 |
| ALCc (>1) | 0.61 | 0.35–1.04 | 0.068 | 0.88 | 0.47–1.65 | 0.683 |
| miRisk (high vs low) | 4.35 | 2.41–7.85 | <0.001 | 3.83 | 1.99–7.37 | <0.001 |
| Independent validation cohort | ||||||
|---|---|---|---|---|---|---|
| PD-L1 (≥50%) | 1.67 | 0.95–2.94 | 0.073 | 1.54 | 0.45–5.31 | 0.492 |
| ECOGa (>0) | 2.82 | 1.47–5.41 | 0.002 | 4.46 | 2.15–9.24 | <0.001 |
| Gender (male vs female) | 1.07 | 0.6–1.93 | 0.816 | 0.81 | 0.43–1.52 | 0.508 |
| Age (>75 years) | 1.66 | 0.85–3.24 | 0.141 | 1.81 | 0.87–3.81 | 0.115 |
| Therapy line incl. <IV (>2) | 1.36 | 0.73–2.54 | 0.327 | 1.32 | 0.67–2.58 | 0.421 |
| Substance (Pembro vs Nivo) | 0.68 | 0.39–1.19 | 0.176 | 1.18 | 0.35–4.01 | 0.789 |
| Histology (Non-adeno vs adeno) | 1.63 | 0.93–2.85 | 0.088 | 1.59 | 0.81–3.12 | 0.174 |
| Smoking status (ever smoker vs other) | 1.92 | 0.46–7.96 | 0.367 | 4.53 | 0.98–20.99 | 0.054 |
| ANCb (>7.5) | 1.98 | 1.08–3.62 | 0.027 | 1.06 | 0.54–2.11 | 0.862 |
| ALCc (>1) | 0.57 | 0.32–0.99 | 0.047 | 0.68 | 0.38–1.22 | 0.200 |
| miRisk (high vs low) | 2.47 | 1.36–4.48 | 0.003 | 2.49 | 1.16–5.34 | 0.019 |
| Control cohort | ||||||
|---|---|---|---|---|---|---|
| PD-L1 (≥50%) | 1.46 | 0.64–3.32 | 0.364 | 1.59 | 0.65–3.87 | 0.307 |
| ECOGa (>0) | 1.66 | 0.85–3.25 | 0.136 | 2.13 | 1.05–4.35 | 0.037 |
| Gender (male vs female) | 1.14 | 0.59–2.20 | 0.698 | 1.06 | 0.52–2.16 | 0.878 |
| Age (>75 years) | 0.75 | 0.27–2.12 | 0.590 | 0.52 | 0.17–1.56 | 0.241 |
| Histology (Non-adeno vs adeno) | 0.93 | 0.42–2.03 | 0.851 | 0.69 | 0.31–1.53 | 0.360 |
| Smoking status (ever smoker vs other) | 0.90 | 0.28–2.91 | 0.854 | 0.76 | 0.21–2.68 | 0.664 |
| ANCb (>7.5) | 0.47 | 0.25–0.90 | 0.022 | 0.37 | 0.18–0.75 | 0.006 |
| ALCc (>1) | 0.96 | 0.50–1.82 | 0.893 | 0.91 | 0.45–1.82 | 0.787 |
| miRisk (high vs low) | 1.36 | 0.70–2.64 | 0.369 | 2.52 | 1.20–5.30 | 0.015 |
aEastern Cooperative Oncology Group (ECOG) performance status.
bAbsolute neutrophil count.
cAbsolute lymphocyte count.